Melody Chang, R.Ph., says payers cover bispecific and CAR-T drugs but not the monitoring that lets community practices deliver them safely at lower cost.
|Articles|December 26, 2013
7 reasons for slower spending growth
NEJM researchers find the reasons behind the slowdown
Advertisement
- Fewer blockbuster drugs
- Slower growth in existing technologies
- Higher out-of-pocket costs for members
- Penalties for hospital-acquired conditions
- Penalties for preventable readmissions
- Accountable care
- Bundled payment
According to the New England Journal of Medicine, last year healthcare spending rose only moderately for the third year in a row, increasing by 0.8% per person, slightly less than the rate of growth of gross domestic product per capita. This trend marks a departure from the previous five decades, and may be fueled in part by payment reforms contained within the Affordable Care Act.
Source:
Advertisement
Related to this article
Continuous glucose monitoring cut mean A1C from 8.8% to 7.2% over 26 weeks in adults with type 2 diabetes not on insulin, 0.9 points more than routine care in the CONNECT trial.
American Oncology Network’s Melody Chang, R.Ph., says 18% of its first 70 outpatient bispecific patients had CRS, all low grade with no hospitalizations.
A screening program in eight countries found early-stage type 1 diabetes in about 1 in 350 children with no family history of the disease.
Healthcare leaders should be preparing now for important changes in prior authorization and other areas of healthcare.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say research justifies services and opens doors to limited distribution drugs.
Garza, an expert on hidradenitis suppurativa at Johns Hopkins, says increasing incidence of the disease on the Japanese island of Okinawa offer some "tantalizing clues" about reasons for the rising incidence.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
2
More checks in the plus column for GLP-1s for obstructive sleep apnea | CHEST 2026
3
Rex Hoffman, M.D., on how a CMO balances competing priorities | HSES 2026
4
Algia Pharma completes investigational drug toxicology study for non-opioid acute pain regimen AlgiaPak
5